Transfusion and Apheresis Science最新文献

{"title":"Impact of the national blackout of April 28, 2025 on processing facilities for hematopoietic stem cell transplantation and cell therapy in Spain","authors":"Oscar M. Pello , Maria E. Martinez-Muñoz , Jose Luis Arroyo, Jesus Fernandez-Sojo, Anna Sureda, Fermin Sanchez-Guijo, on behalf of the Spanish Group for Cryobiology and Cell Therapy (GETCC-SEHH)","doi":"10.1016/j.transci.2025.104257","DOIUrl":"10.1016/j.transci.2025.104257","url":null,"abstract":"","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"64 6","pages":"Article 104257"},"PeriodicalIF":1.2,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145220534","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reticulocyte hemoglobin: A useful tool for detecting rampant iron-deficient state in regular female blood donors","authors":"T. Divya ,&nbsp;Richa Gupta ,&nbsp;Surender Vats ,&nbsp;Mrinalini Kotru","doi":"10.1016/j.transci.2025.104258","DOIUrl":"10.1016/j.transci.2025.104258","url":null,"abstract":"<div><h3>Background and objective</h3><div>Regular blood donors are at risk of developing Latent Iron Deficiency (LID), most commonly seen in female blood donors. Although female blood donors outnumber males in some populations, latent iron deficiency may limit the ability of young females to donate regularly. Current blood donor selection guidelines only screen for pre-donation hemoglobin levels, potentially missing those with LID, which leads to overt iron deficiency later. The gold standard for diagnosing LID is serum transferrin receptor level (sTfR). However, it may not be practical as a screening tool due to its high cost. Therefore, the present study aimed to find the utility of Reticulocyte Hemoglobin (Ret-He) in detecting LID and compare it with serum ferritin among regular female blood donors.</div></div><div><h3>Methods</h3><div>The study included 161 female regular blood donors who consented to participate in the study. Subjects were divided into two groups- LID and non-LID based on sTfR levels. Ret-He and Serum ferritin levels were compared between the two groups.</div></div><div><h3>Results</h3><div>The study found 37.25 % of LID donors among regular female blood donors. Donors with LID had significantly lower mean Ret-He levels (25.6 ± 1.54 pg/dL) than non-LID donors (27.9 ± 1.49 pg/dL). Also, Ret-He had higher sensitivity (83.3 %) and specificity (85.1 %) than serum ferritin.</div></div><div><h3>Conclusion</h3><div>LID is highly prevalent among regular female blood donors. Ret-He can be used as a screening tool for iron status in female regular blood donors, thus preventing overt iron deficiency due to donation.</div></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"64 6","pages":"Article 104258"},"PeriodicalIF":1.2,"publicationDate":"2025-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145214126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The emerging roles of ACKR1/Duffy antigen beyond malaria","authors":"Roshan Shaikh ,&nbsp;Kanjaksha Ghosh ,&nbsp;Ajit Gorakshakar","doi":"10.1016/j.transci.2025.104255","DOIUrl":"10.1016/j.transci.2025.104255","url":null,"abstract":"<div><div>Atypical chemokine receptor 1 (ACKR1), formerly known as the Duffy antigen/receptor for chemokines (DARC), has been primarily recognized for its role in <em>Plasmodium vivax</em> invasion of erythrocytes. Recent research has unveiled its diverse functions beyond malaria like susceptibility in inflammation, cancer biology, hematopoiesis, and several diseases. This perspective highlights these emerging roles and their potential therapeutic applications.</div></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"64 6","pages":"Article 104255"},"PeriodicalIF":1.2,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145049100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of anticoagulant used for peripheral blood collection on NK cell yield, function, and proliferation","authors":"Catherine A. Cash ,&nbsp;Dean A. Lee","doi":"10.1016/j.transci.2025.104253","DOIUrl":"10.1016/j.transci.2025.104253","url":null,"abstract":"<div><div>Natural killer (NK) cells are under investigation for cellular immunotherapy of cancer, infectious diseases, and autoimmunity. The collection of autologous or allogeneic starting material for the expansion of NK cells - whether whole blood, cord blood, or leukocyte apheresis - requires the use of anticoagulants. Heparin and acid citrate dextrose A (ACD-A) are most commonly used for collection, but their impact on NK cells has not been clearly described. As functional impairment has been described for irreversible calcium chelation with EDTA, we hypothesized that prolonged calcium chelation by ACD-A might also have an adverse impact on NK cell health, particularly with prolonged exposure. To test this hypothesis, peripheral blood was collected as paired samples in heparin and in ACD-A, stored for 24 h at room temperature, and then tested for viable NK cell yield and proliferative capacity for 2 weeks under <em>ex vivo</em> expansion. Both conditions yielded similar viability and T/NK cell content after initial isolation. However, compared to ACD-A-treated blood, heparin-treated blood provided a mean 23 % higher initial yield of NK cells (p = 0.03) and a non-significant trend toward greater fold expansion, which resulted in 60 % higher overall yield after expansion (p = 0.048). These data suggest that both ACD-A and heparin can be used for NK cell collection, but that heparin may be the preferred anticoagulant if there is an expected delay in the product processing such as a pause for overnight testing or shipping. Process development for cellular therapeutics should assess the impact of anticoagulant used for cell collection.</div></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"64 6","pages":"Article 104253"},"PeriodicalIF":1.2,"publicationDate":"2025-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145060922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A novel variant of MYH9 mutation associated macro-thrombocytopenia: A case series","authors":"Sarthak Wadhera ,&nbsp;Ritika Sharma ,&nbsp;Aarushi Sahni ,&nbsp;Rudra Narayan Swain ,&nbsp;Reena Das ,&nbsp;Pankaj Malhotra ,&nbsp;Jasmina Ahluwalia","doi":"10.1016/j.transci.2025.104254","DOIUrl":"10.1016/j.transci.2025.104254","url":null,"abstract":"<div><h3>Background</h3><div>MYH9-related disease (MYH9-RD) is a rare autosomal dominant disorder characterized by macro-thrombocytopenia and variable extra-hematological manifestations including sensorineural hearing loss (SNHL), nephropathy, and cataracts. Due to its phenotypic overlap with immune thrombocytopenia (ITP), it is often misdiagnosed, leading to inappropriate treatment.</div></div><div><h3>Objective</h3><div>To report a novel MYH9 gene variant in a family with syndromic macro-thrombocytopenia and to highlight the therapeutic benefit of thrombopoietin receptor agonists in symptomatic individuals.</div></div><div><h3>Case report</h3><div>The index case, a 22-year-old male with mucocutaneous bleeding and bilateral SNHL, showed poor response to corticosteroids. NGS identified a novel heterozygous variant in the MYH9 gene (c.130_131delinsAA; p.Ala44Asn), located in the conserved head domain of NMMHC-IIA. The variant segregated in four other affected family members, two of whom had SNHL and one had cataract. Symptomatic individuals treated with Eltrombopag achieved sustained improvements in platelet counts and resolution of bleeding.</div></div><div><h3>Conclusion</h3><div>This report identifies a novel pathogenic MYH9 variant associated with syndromic macro-thrombocytopenia and emphasizes the importance of recognizing inherited thrombocytopenia. Early diagnosis avoids unnecessary immunosuppression and allows for appropriate use of thrombopoietin receptor agonists, genetic counselling, and surveillance for extra-hematological complications.</div></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"64 6","pages":"Article 104254"},"PeriodicalIF":1.2,"publicationDate":"2025-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145027194","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Therapeutic plasma exchange in immune thrombotic thrombocytopenic purpura: A six-year prospective study on clinical efficacy, laboratory trends, and sex-based differences","authors":"Sudipta Sekhar Das,&nbsp;Sourav Mukherjee,&nbsp;Sourav Chowdhury","doi":"10.1016/j.transci.2025.104252","DOIUrl":"10.1016/j.transci.2025.104252","url":null,"abstract":"<div><div>Thrombotic thrombocytopenic purpura (TTP) is a life-threatening thrombotic microangiopathy characterized by severe ADAMTS13 deficiency. Therapeutic plasma exchange (TPE) remains the cornerstone of treatment in immune-mediated TTP. However, limited data are available from India on procedural characteristics, sex-based presentation, and laboratory response dynamics. This six-year prospective observational study enrolled 43 patients with immune TTP at a tertiary care center in Eastern India between January 2019 and December 2024. All patients had ADAMTS13 activity &lt; 10 % and received corticosteroids and daily TPE. Clinical features, laboratory parameters, procedural metrics, and treatment outcomes were analyzed. The cohort had a female predominance (72.1 %) with a mean age of 36.1 ± 9.6 years. All patients underwent ≥ 6 TPE sessions using central venous access. Significant hematologic improvement was observed: hemoglobin rose from 6.6 g/dL to 11.1 g/Dl (p = 0.00001), platelets from 17.4 to 157.7 × 10⁶/mL (p &lt; 0.001), and LDH declined from 1121.6 to 229.7IU/L (p &lt; 0.001). Reticulocyte count and indirect bilirubin levels decreased, indicating hemolysis resolution. Procedure-related adverse events were mild (20.9 %) and manageable. Females exhibited more severe anemia and higher bilirubin levels than males, while LDH levels were higher in males, suggesting sexbased variation in disease severity. The overall mortality rate was 16.3 %, predominantly among females. TPE combined with corticosteroids led to rapid hematologic recovery and was safe and effective in immune TTP. Baseline gender disparities and the lack of adjunctive biologics highlight the need for tailored treatment protocols and improved access to advanced therapies in resource-constrained settings.</div></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"64 6","pages":"Article 104252"},"PeriodicalIF":1.2,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145027256","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends in cell collection and apheresis practices: Insights from a cross-sectional study on the use of Spectra Optia in collection and transplant centers","authors":"Nabih Azar ,&nbsp;Nelson J. Chao ,&nbsp;Manuel Cliquennois ,&nbsp;Maria Geske ,&nbsp;Tomoko Henzan ,&nbsp;Tamarah Kent ,&nbsp;Pascale Poullin ,&nbsp;Tsiporah B. Shore ,&nbsp;Matthew Cawson ,&nbsp;Hugo Fabre ,&nbsp;Franziska Waltl","doi":"10.1016/j.transci.2025.104251","DOIUrl":"10.1016/j.transci.2025.104251","url":null,"abstract":"<div><h3>Background</h3><div>This study, conducted among collection and transplant centers in France, Germany, Japan, the United Kingdom (UK), and the United States (USA), aimed to better understand current trends, challenges, and future directions in cell collection and apheresis practices, focusing on the Spectra Optia™ Apheresis System.</div></div><div><h3>Methods</h3><div>This cross-sectional study was conducted from July to November 2023 among facilities using the Spectra Optia™ Apheresis System, which could also be using other comparable cell collection technologies, with expertise in cell collection and therapeutics. Respondents completed an online questionnaire.</div></div><div><h3>Results</h3><div>Forty-four facilities (France: 9, Germany: 7, Japan: 7, UK: 6, USA: 15) consented to participate. Across participating centers, a marked trend towards autologous cell collections was evident in France (mean: 71 % of collections were for autologous purposes), Germany (74 %), UK (79 %), and USA (73 %). Among centers in Japan, a more balanced division between autologous (47 %) and allogeneic (53 %) collections was seen. Over half of all respondents indicated facing several key challenges, including issues related to supporting services, patients, logistics, purity, and technology. The respondents largely agreed that the cell therapy demand will increase over the next 3–5 years and estimated a growth of 10–200 %.</div></div><div><h3>Conclusions</h3><div>This study highlights the breadth of indications for which Spectra Optia is used, and the dynamic nature and growth prospects of the field. Innovation and standardization in apheresis technologies will be important to drive the potential of cell-based therapeutics.</div></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"64 6","pages":"Article 104251"},"PeriodicalIF":1.2,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145020339","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mob-Marly: A Latin American experience in hematopoietic stem cell mobilization for autologous transplantation","authors":"Óscar Peña ,&nbsp;Licet Villamizar ,&nbsp;Paola Charry ,&nbsp;Tatiana Camargo ,&nbsp;Enrique Pedraza ,&nbsp;Joan Cid","doi":"10.1016/j.transci.2025.104244","DOIUrl":"10.1016/j.transci.2025.104244","url":null,"abstract":"<div><h3>Background</h3><div>Hematopoietic stem cell (HSC) mobilization is a critical step in autologous transplantation for patients with multiple myeloma and lymphoma. While several risk factors for mobilization failure have been identified, real-world data from Latin America remain limited. This study aimed to describe mobilization outcomes and associated factors in a transplant center in Colombia.</div></div><div><h3>Methods</h3><div>We conducted a retrospective cohort study including patients with multiple myeloma or lymphoma who initiated HSC mobilization between 2019 and 2023 at Clínica de Marly in Bogotá, Colombia. The primary outcome was mobilization success, defined as the collection of at least 2 × 10⁶ CD34⁺ cells/kg. We analyzed clinical, treatment-related, and laboratory variables using univariate and multivariate logistic regression to identify factors associated with mobilization success or failure.</div></div><div><h3>Results</h3><div>A total of 414 patients were included; the overall mobilization success rate was 86.7 %. In multivariate analysis, previous mobilization failure (OR 0.035, p &lt; 0.001), age ≥ 65 years (OR 0.94, p = 0.003), and lymphoma diagnosis (OR 0.39, p = 0.02) were independently associated with mobilization failure. CD34⁺ counts on days + 4 and + 5 were strong predictors of successful mobilization, with thresholds of &gt; 10 × 10⁶/L and &gt; 20 × 10⁶/L, respectively. Currently, at our center, the standard mobilization regimen consists of filgrastim 10 µg/kg/day for five days, with just-in-time plerixafor administered based on CD34⁺ monitoring results.</div></div><div><h3>Conclusion</h3><div>Hematopoietic stem cell (HSC) mobilization remains a multifactorial challenge influenced by patient-, disease-, and treatment-related factors. Our findings underscore the importance of early identification of poor mobilizers and support the use of CD34⁺ monitoring and just-in-time plerixafor as effective strategies to optimize mobilization outcomes, particularly in resource-limited settings.</div></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"64 6","pages":"Article 104244"},"PeriodicalIF":1.2,"publicationDate":"2025-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144922595","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Frequency of maternal red blood cell alloantibodies and clinical utility of antibody screening in Abuja, Nigeria","authors":"Irouno Ijeoma Perpetual ,&nbsp;Amaechi Rose Akubueziuka ,&nbsp;Dic-Ijiewere Ebenezer Oseremen ,&nbsp;Otumu Odianosen Sunday","doi":"10.1016/j.transci.2025.104243","DOIUrl":"10.1016/j.transci.2025.104243","url":null,"abstract":"<div><h3>Background</h3><div>Pregnancy causes immunisation when the fetal red cells, possessing a paternal antigen foreign to the mother, enter the maternal circulation, resulting in the production of alloantibodies. Maternal allo-immunisation, also known as iso-immunization, occurs when a woman’s immune system is sensitised to foreign erythrocyte surface antigens, stimulating the production of immunoglobulin G (IgG) antibodies. This study was carried out to determine the frequency of maternal Red blood cell alloantibodies in Gwarimpa General Hospital, FCT, Abuja, and to evaluate the clinical utility of antibody screening.</div></div><div><h3>Methods</h3><div>This was a prospective cross-sectional study involving 250 pregnant women aged 16–45 years recruited from an antenatal care clinic within the period of 6 months. Serum grouping and ABO blood grouping was done using the tube method. Indirect antibody testing was used for antibody screening, using DiaCeLL I + II + III Screening Cells (DiaMed AG, Switzerland), while indirect antiglobulin test was used for antibody identification on all positive cell samples using DiaPanel cells (DiaMed AG, Switzerland).</div></div><div><h3>Result</h3><div>The result of the study showed that 29.8 % of the study participants have had two pregnancies; only 1.2 % have had greater than 4 pregnancies. The most frequently occurring irregular antibody detected was anti-E; 3 (1.2 %), followed by anti-K; 2 (0.8 %), then anti-C and anti-Jsb (0.4 % respectively). Three of the samples had mixed field reactions, while two could not be identified using the panel cell. A blind anti-globulin cross-match carried out on 250 samples revealed that 5 (2.0 %) were incompatible with blood from the same blood group, while 245 (98.0 %) were compatible with blood from the same blood group.</div></div><div><h3>Conclusion</h3><div>Efficiency of the screening method was 48.6 % while the percentage safety of the Antibody screening method was 41.6 %. The immune form of anti-E is able to cause a mild to moderate haemolytic disease of the newborn.</div></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"64 6","pages":"Article 104243"},"PeriodicalIF":1.2,"publicationDate":"2025-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144903892","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anti-M induced severe Hemolytic Disease of the Fetus and Newborn: The role of the Monocyte Monolayer Assay in elucidating the clinical relevance of alloantibodies in pregnancy","authors":"Mariana Martins Godin ,&nbsp;Luciana Cayres Schmidt ,&nbsp;Maria Clara Fernandes da Silva Malta ,&nbsp;Luci Maria SantAna Dusse","doi":"10.1016/j.transci.2025.104241","DOIUrl":"10.1016/j.transci.2025.104241","url":null,"abstract":"<div><h3>Introduction</h3><div>Hemolytic Disease of the Fetus and Newborn (HDFN) is associated with the induction of fetal anemia. Usually, the occurrence of this disease is associated with alloantibodies directed to Rh and K antigens, while severe or fatal cases involving anti-M are rare, especially in non-Asian populations. The Monocyte Monolayer Assay (MMA) is a cellular assay that has been shown to be useful in defining the clinical importance of antibodies.</div></div><div><h3>Case description</h3><div>Severe fetal anemia induced by anti-M was observed in a pregnant 32-year old white Brazilian woman. The immunohematological investigation revealed the presence of two other alloantibodies in the maternal serum. The use of the MMA contributed to elucidating the case, associating only anti-M with the evidenced outcome.</div></div><div><h3>Discussion</h3><div>The presence of anti-M in pregnant women is generally not a concern, as it is commonly identified as a benign IgM antibody of natural origin. However, it can also be present in its IgG isoform of immune origin, which is associated with both destruction of fetal red cells and suppression of erythropoiesis. There is still no consensus among professionals for the monitoring of pregnant women through the titration of anti-M. In this context, MMA may be useful to clarify the unfavorable outcomes observed in pregnancies of alloimmunized women.</div></div><div><h3>Conclusion</h3><div>The present report describes a rare case of severe fetal anemia associated with maternal anti-M in a Brazilian woman and how MMA assisted to elucidate the clinical relevance of the alloantibodies detected.</div></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"64 5","pages":"Article 104241"},"PeriodicalIF":1.2,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144896028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}